La cadena de opciones muestra datos clave de las opciones de acciones de Reviva Pharmaceuticals a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Reviva Pharmaceuticals..

Reviva Pharmaceuticals (NASDAQ:RVPH) Bolsa, Cadena de Opciones

Reviva Pharmaceuticals

Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, and Parkinson's disease psychosis and its other drug candidate is RP1208.

Reviva Pharmaceuticals Holdings, Inc. - Common Stock

Reviva Pharmaceuticals Holdings Inc

Reviva Pharmaceuticals Holdings, Inc. - Warrants

RBC Capital analyst Jimmy Shan maintains Minto Apartment (TSX:<a class="ticker" href="https://www.benzinga.com/stock/MI#TSX">MI</a>) with a Outperform and lowers the price target from C$21.5 to C$20.5.

News

Price Target

Analyst Ratings

TSX:MI

TSX:MI/UN

RBC Capital Maintains Outperform on Minto Apartment, Lowers Price Target to C$20.5

Trading Ideas

PXDT

Pixie Dust Technologies Shares Halted On Circuit Breaker To The Upside, Stock Now Up 108.9%

Goldman Sachs analyst Mike Niehuser maintains Nu Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NU#NYSE">NU</a>) with a Buy and raises the price target from $17 to $19.

Goldman Sachs Maintains Buy on Nu Holdings, Raises Price Target to $19

Canaccord Genuity analyst John Newman maintains BioNTech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTX#NASDAQ">BNTX</a>) with a Buy and maintains $171 price target.

BNTX

Canaccord Genuity Maintains Buy on BioNTech, Maintains $171 Price Target

RBC Capital analyst Douglas Miehm reiterates Oncolytics Biotech (TSX:<a class="ticker" href="https://www.benzinga.com/stock/ONC#TSX">ONC</a>) with a Outperform and maintains C$6 price target.

Reiteration

ONCY

TSX:ONC

RBC Capital Reiterates Outperform on Oncolytics Biotech, Maintains C$6 Price Target

Exxon Mobil Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XOM#NYSE">XOM</a>) shares are trading higher by roughly 5% during November after Donald Trump's win in the <a href="https://www.benzinga.com/economics/macro-economic-events/24/11/41772701/trumps-historic-return-7-ways-his-second-term-could-impact-the-us-economy">presidential election</a>, as investors anticipate a more favorable regulatory and economic environment for the oil and gas sector.
Trump's administration is expected to prioritize fossil fuel production, potentially reversing recent policies on environmental restrictions and supporting domestic energy expansion, which could directly benefit Exxon's extensive U.S. operations. 
Trump's stance on reducing regulations in the energy sector could make it easier and more cost-effective for Exxon to expand drilling projects, especially in U.S. shale regions like the Permian Basin, where the company has invested heavily in recent years.
Read Also: <a href="https://www.benzinga.com/tech/24/11/41973572/ray-dalios-bridgewater-cuts-stake-in-microsoft-stock-by-20-is-big-tech-losing-its-shine">Ray Dalio&#8217;s Bridgewater Cuts Stake In Microsoft Stock By 20% – Is Big Tech Losing Its Shine?</a>
What To Know: One anticipated shift under Trump's policies would be a rollback of regulations tied to carbon emissions, methane leaks, and drilling permits, which had increased compliance costs for companies like Exxon. 
With eased regulatory pressures, Exxon would have greater flexibility to explore and develop new oil and gas fields without facing stringent environmental compliance costs, potentially boosting production levels and profitability. 
Additionally, Trump's proposal to withdraw from the Paris Climate Agreement and possibly undo green energy subsidies could slow the U.S. transition to renewables, extending the market dominance of traditional energy sources where Exxon is well-positioned.
Read Also: <a href="https://www.benzinga.com/24/11/41971559/disneys-q4-boosted-by-streaming-gains-strong-box-office-and-solid-parks-performance">Disney Q4 Earnings: Revenue And Profit Beat, Best Film Studio Performance, 3-Year Outlook And More</a>
What Else: Trump's protectionist trade policies, particularly his advocacy for tariffs on foreign imports, could also play a role in shaping Exxon's strategy. 
While higher tariffs could increase costs for some imported materials used in refining and exploration, the overarching goal to strengthen domestic energy independence aligns with Exxon's core U.S. operations. 
Furthermore, Trump's inclination to ease sanctions on certain countries, such as Russia, could create new avenues for Exxon to partner in international projects, a potential growth area constrained by recent sanctions.
While uncertainties remain in the global oil market, Trump's commitment to bolstering fossil fuel production and easing regulatory constraints provides an optimistic outlook for Exxon's growth trajectory, making the stock an appealing choice for energy investors post-election.
Read Also: <a href="https://www.benzinga.com/economics/macro-economic-events/24/11/41971830/producer-inflation-rises-more-than-expected-in-october-should-traders-rethink-interest-rate-cut-path">Producer Inflation Rises More Than Expected In October: Should Traders Rethink Interest Rate Cut Path?</a>
<h2 class="wp-block-heading">How To Buy XOM Stock</h2>
By now you're likely curious about how to participate in the market for Exxon Mobil &#8211; be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy ‘fractional shares,' which allows you to own portions of stock without buying an entire share. For example, some stock, like Berkshire Hathaway, can cost thousands of dollars to own just one share. However, if you only want to invest a fraction of that, brokerages will allow you to do so.
In the the case of Exxon Mobil, which is trading at $121.61 as of publishing time, $100 would buy you 0.82 shares of stock.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to ‘go short' a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, XOM has a 52-week high of $126.34 and a 52-week low of $95.77.

What's Going On With Exxon Mobil (XOM) Stock?

Goldman Sachs analyst Mark Delaney maintains Luminar Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LAZR#NASDAQ">LAZR</a>) with a Sell and lowers the price target from $0.75 to $0.5.

LAZR

Goldman Sachs Maintains Sell on Luminar Technologies, Lowers Price Target to $0.5

Salesforce Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRM#NYSE">CRM</a>) is aggressively embracing AI in enterprise software. CEO Marc Benioff is positioning the company&#8217;s AI agents as the industry&#8217;s next significant evolution.
The company plans to deploy software bots that can handle various tasks autonomously, aiming to streamline operations and reduce the workload for human employees.
Also Read: <a target="_blank" href="https://www.benzinga.com/top-stories/24/10/41428765/microsoft-salesforce-battle-heats-up-as-ai-agent-technology-takes-center-stage" rel="noreferrer noopener">Microsoft, Salesforce Battle Heats Up As AI Agent Technology Takes Center Stage</a>
During a recent episode of the Equity podcast, Benioff shared his vision, underscoring how this shift could reshape enterprise software as we know it.
Benioff emphasized the potential of these AI agents to revolutionize productivity by extending workforce capabilities without limitations, TechCrunch <a target="_blank" href="https://techcrunch.com/podcast/marc-benioff-says-its-crazy-talk-that-ai-will-hurt-salesforce-wants-a-billion-ai-agents-in-a-year/" rel="noreferrer noopener">reports</a>.
The Salesforce chief noted that hundreds of companies already leverage <a target="_blank" href="https://www.benzinga.com/markets/equities/24/10/41607435/salesforce-launches-agentforce-redefining-ai-in-business-with-autonomous-solutions" rel="noreferrer noopener">the Agentforce platform</a>, an AI-driven tool enabling autonomous task execution across business functions.
He set an ambitious target of deploying a billion AI agents within a year, showcasing this technology&#8217;s scalability and market demand.
Benioff shared a personal example from a recent visit to a Disney park, using the company&#8217;s virtual tour guide feature. The AI agent analyzed historical ride preferences and current park traffic, suggesting customized itineraries.
This personalized approach demonstrated how AI can enhance user experiences across different sectors, including entertainment, retail, and healthcare.
While Salesforce continues to develop its Agentforce platform, Benioff criticized Microsoft Corp&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) AI offerings and expressed skepticism about Microsoft&#8217;s Copilot agents. He cited user complaints and research indicating security and functionality issues with Microsoft&#8217;s solutions.
Despite the rise of new AI-focused startups, Benioff remains confident in Salesforce&#8217;s position.
Benioff emphasized that Salesforce&#8217;s secure data infrastructure sets it apart, enabling more reliable AI-driven insights and services.
As part of its growth strategy, Salesforce uses its own AI agents internally across various departments, including customer service and sales.
<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="750" height="650" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/14093208/newplot-8.png" alt="" class="wp-image-648092" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/14093208/newplot-8.png 750w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/14093208/newplot-8-300x260.png 300w" sizes="(max-width: 750px) 100vw, 750px" /></figure>
Northland Capital Partners said Salesforce&#8217;s AgentForce platform <a target="_blank" href="https://www.benzinga.com/top-stories/24/10/41145130/salesforces-genai-platform-agentforce-on-par-with-microsoft-analyst" rel="noreferrer noopener">is &#8220;on par&#8221; with</a> Microsoft.
Jim Cramer, host of CNBC&#8217;s &#8220;Mad Money,&#8221; praised Salesforce for its <a target="_blank" href="https://www.benzinga.com/markets/equities/24/11/41890694/jim-cramer-says-salesforce-agentforce-is-the-best-use-of-ai-he-has-seen-makes-sense-that-the-stock-has-gone-up-so-much" rel="noreferrer noopener">innovative AI product</a>, Agentforce, crediting the tool for driving the recent surge in the company&#8217;s stock.
Cramer shared his views on X, describing Agentforce as &#8220;pretty revolutionary.&#8221; He pointed out that the stock&#8217;s upward movement aligns with the impact of this cutting-edge AI solution and highlighted it as the most effective AI use case he has seen, validating the stock&#8217;s rally.
Salesforce&nbsp;stock surged over 33% year-to-date. Investors can gain exposure to the stock through SPDR Select Sector Fund &#8211; Technology (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>) and Vanguard Total Stock Market ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTI#NYSE">VTI</a>).
Price Action: CRM stock is down 2.18% at $334.28 at the last check on Thursday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/24/11/41971559/disneys-q4-boosted-by-streaming-gains-strong-box-office-and-solid-parks-performance" target="_blank" rel="noreferrer noopener">Disney Q4 Earnings: Revenue And Profit Beat, Best Film Studio Performance, 3-Year Outlook And More</a></li>
</ul>
Photo by NYCStock via Shutterstock

Management

Tech

Media

MSFT

Salesforce CEO Marc Benioff Bets Big on Billion Bots

Canaccord Genuity analyst Sumant Kulkarni maintains Zevra Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZVRA#NASDAQ">ZVRA</a>) with a Buy and lowers the price target from $25 to $23.

ZVRA

Canaccord Genuity Maintains Buy on Zevra Therapeutics, Lowers Price Target to $23

RBC Capital analyst Michael Harvey reiterates Peyto Exploration &amp; Dev (TSX:<a class="ticker" href="https://www.benzinga.com/stock/PEY#TSX">PEY</a>) with a Sector Perform and maintains C$17 price target.

TSX:PEY

RBC Capital Reiterates Sector Perform on Peyto Exploration & Dev, Maintains C$17 Price Target

Goldman Sachs analyst Ryan Nash maintains loanDepot (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LDI#NYSE">LDI</a>) with a Sell and raises the price target from $1.7 to $2.7.

Goldman Sachs Maintains Sell on loanDepot, Raises Price Target to $2.7

On Thursday, Immutep Limited&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMMP#NASDAQ">IMMP</a>) released data from the INSIGHT-003 Phase 1 trial of eftilagimod alpha (efti) in combination with Merck &amp; Co Inc&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) Keytruda (pembrolizumab) and chemotherapy for first-line treatment of metastatic non-squamous non-small cell lung <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/g41970785/immuteps-efti-shows-excellent-survival-data-from-insight-003-trial-in-non-small-cell-lung-cancer" rel="noreferrer noopener">cancer (1L NSCLC) patients</a>.
The survival data as of data cutoff of Oct. 15 from the triple combination therapy in patients irrespective of PD-L1 expression with a minimum followup of 22 months (N=21) shows:
<ul>
<li>Median Overall Survival (OS) of 32.9 months.</li>
<li>Median Progression-Free Survival (PFS) of 12.7 months.</li>
<li>24-month Overall Survival (OS) of 81.0%.</li>
</ul>
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/07/39747049/australia-based-cancer-focused-immuteps-lead-cancer-drug-shows-meaningful-response-in-untreated-h" rel="noreferrer noopener">Australia Based Cancer Focused Immutep&#8217;s Lead Cancer Drug Shows &#8216;Meaningful Response&#8217; In Untreated Head &amp; Neck Cancer, Stock Soars</a>
The company compares the data with the 22.0-month median OS, 9.0-month median PFS, and 24-month OS rate of 45.5% from a registrational trial of anti-PD-1 and doublet chemotherapy in non-squamous 1L NSCLC regardless of PD-L1 expression.
Marc Voigt, CEO of Immutep, said, &#8220;The overall survival and progression-free survival data from this mature cohort of patients in INSIGHT-003 with nearly a 2-year minimum followup exceeds our expectations.&#8221;
Data from all evaluable patients to date (N=40) demonstrates significant improvement in Overall Response Rate (ORR) across all levels of PD-L1 expression compared to historical control:
<ul>
<li>75.0% ORR versus 62.1% ORR in patients with high PD-L1 expression.</li>
<li>58.8% ORR versus 49.2% ORR in patients with low PD-L1 expression.</li>
<li>47.4% ORR versus 32.3% ORR in patients with negative PD-L1.</li>
<li>In this all-comer PD-L1 trial, the 55.0% ORR and 87.5% Disease Control Rate (DCR) are from the following breakdown of patients by PD-L1 expression: high PD-L1 expression (N=4), low PD-L1 expression (N=17), and negative PD-L1 (N=19).</li>
<li>Compared to the general 1L NSCLC patient population, each of these PD-L1 levels represents roughly one-third, INSIGHT-003 is biased towards low and negative PD-L1 patients who are typically less responsive to anti-PD-1 therapy.</li>
<li>In these patients with low and negative PD-L1 expression (36 of 40 patients), the triple combination achieved a 52.8% ORR and 86.1% DCR.</li>
</ul>
INSIGHT-003, a multi-centre study led by the Frankfurt Institute of Clinical Cancer Research IKF, is nearing completion of patient enrolment.
Additional data updates from this trial are expected in 2025 and beyond.
Price Action: IMMP stock is up 9.6% at $2.05 at last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/11/41970133/exclusive-adial-pharmaceuticals-reveals-topline-results-from-pharmacokinetics-study-of-ad04-for-alcohol-use-disorder" target="_blank" rel="noreferrer noopener">EXCLUSIVE: Adial Pharmaceuticals Reveals Topline Results From Pharmacokinetics Study Of AD04 For Alcohol Use Disorder</a></li>
</ul>
Photo: Shutterstock

Biotech

Health Care

Movers

General

IMMP

Immutep's Lead Cancer Drug Shows Promising 2-Year Survival Data In Lung Cancer Trial

Whales with a lot of money to spend have taken a noticeably bearish stance on Shopify.
Looking at options history for Shopify (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHOP#NYSE">SHOP</a>) we detected 42 trades.
If we consider the specifics of each trade, it is accurate to state that 26% of the investors opened trades with bullish expectations and 52% with bearish.
From the overall spotted trades, 9 are puts, for a total amount of $691,916 and 33, calls, for a total amount of $5,852,437.
<h3>Predicted Price Range</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $40.0 to $120.0 for Shopify over the last 3 months. 
<h3>Insights into Volume &amp; Open Interest</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Shopify's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Shopify's whale trades within a strike price range from $40.0 to $120.0 in the last 30 days. 
<h3>Shopify 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731600949_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>SHOP</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>06/20/25</td>
<td>$29.4</td>
<td>$28.8</td>
<td>$29.04</td>
<td>$90.00</td>
<td>$1.1M</td>
<td>4.3K</td>
<td>2.0K</td>
</tr>
<tr>
<td>SHOP</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$22.7</td>
<td>$22.0</td>
<td>$22.7</td>
<td>$115.00</td>
<td>$1.1M</td>
<td>2.2K</td>
<td>1.8K</td>
</tr>
<tr>
<td>SHOP</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$22.6</td>
<td>$22.4</td>
<td>$22.4</td>
<td>$115.00</td>
<td>$672.0K</td>
<td>2.2K</td>
<td>1.8K</td>
</tr>
<tr>
<td>SHOP</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>06/20/25</td>
<td>$15.9</td>
<td>$15.15</td>
<td>$15.54</td>
<td>$115.00</td>
<td>$634.6K</td>
<td>6.0K</td>
<td>2.0K</td>
</tr>
<tr>
<td>SHOP</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$15.55</td>
<td>$15.15</td>
<td>$15.48</td>
<td>$115.00</td>
<td>$485.3K</td>
<td>6.0K</td>
<td>2.0K</td>
</tr>
</tbody>
</table>

<h3>About Shopify</h3>
Shopify offers an e-commerce platform primarily to small and medium-size businesses. The firm has two segments. The subscription solutions segment allows Shopify merchants to conduct e-commerce on a variety of platforms, including the company's website, physical stores, pop-up stores, kiosks, social networks (Facebook), and Amazon. The merchant solutions segment offers add-on products for the platform that facilitate e-commerce and include Shopify Payments, Shopify Shipping, and Shopify Capital.
In light of the recent options history for Shopify, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Where Is Shopify Standing Right Now?</h3>
<ul>
<li>With a trading volume of 5,624,338, the price of SHOP is down by -4.56%, reaching $109.84.</li>
<li>Current RSI values indicate that the stock is may be overbought.</li>
<li>Next earnings report is scheduled for 89 days from now.</li>
</ul>
<h3>What Analysts Are Saying About Shopify</h3>
Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $112.4.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Consistent in their evaluation, an analyst from Keybanc keeps a Overweight rating on Shopify with a target price of $130. 
&#x2A; Maintaining their stance, an analyst from Barclays continues to hold a Equal-Weight rating for Shopify, targeting a price of $93. 
&#x2A; Consistent in their evaluation, an analyst from Piper Sandler keeps a Neutral rating on Shopify with a target price of $94. 
&#x2A; Consistent in their evaluation, an analyst from Canaccord Genuity keeps a Buy rating on Shopify with a target price of $125. 
&#x2A; Consistent in their evaluation, an analyst from JMP Securities keeps a Market Outperform rating on Shopify with a target price of $120. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Shopify options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Options

Markets

SHOP

Shopify Unusual Options Activity

Deep-pocketed investors have adopted a bullish approach towards Amgen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in AMGN usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 8 extraordinary options activities for Amgen. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 50% leaning bullish and 25% bearish. Among these notable options, 4 are puts, totaling $137,540, and 4 are calls, amounting to $285,919.
<h3>Projected Price Targets</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $290.0 to $340.0 for Amgen over the recent three months. 
<h3>Insights into Volume &amp; Open Interest</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Amgen's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Amgen's whale activity within a strike price range from $290.0 to $340.0 in the last 30 days. 
<h3>Amgen Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731600944_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>AMGN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$43.6</td>
<td>$43.55</td>
<td>$43.6</td>
<td>$300.00</td>
<td>$196.2K</td>
<td>25</td>
<td align="right">0</td>
</tr>
<tr>
<td>AMGN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$52.8</td>
<td>$51.5</td>
<td>$51.5</td>
<td>$340.00</td>
<td>$51.5K</td>
<td>190</td>
<td align="right">19</td>
</tr>
<tr>
<td>AMGN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$10.3</td>
<td>$9.2</td>
<td>$10.0</td>
<td>$310.00</td>
<td>$38.0K</td>
<td>1.8K</td>
<td align="right">62</td>
</tr>
<tr>
<td>AMGN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>12/20/24</td>
<td>$15.65</td>
<td>$15.2</td>
<td>$15.45</td>
<td>$290.00</td>
<td>$33.9K</td>
<td>1.5K</td>
<td align="right">30</td>
</tr>
<tr>
<td>AMGN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/06/24</td>
<td>$2.95</td>
<td>$2.08</td>
<td>$2.29</td>
<td>$340.00</td>
<td>$26.5K</td>
<td>112</td>
<td align="right">121</td>
</tr>
</tbody>
</table>

<h3>About Amgen</h3>
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
<h3>Amgen's Current Market Status</h3>
<ul>
<li>Currently trading with a volume of 856,173, the AMGN's price is down by -2.03%, now at $295.33. </li>
<li>RSI readings suggest the stock is currently may be oversold.</li>
<li>Anticipated earnings release is in 82 days.</li>
</ul>
<h3>What Analysts Are Saying About Amgen</h3>
Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $360.8.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Bernstein downgraded its action to Outperform with a price target of $380. 
&#x2A; Maintaining their stance, an analyst from Jefferies continues to hold a Buy rating for Amgen, targeting a price of $380. 
&#x2A; In a cautious move, an analyst from Citigroup downgraded its rating to Neutral, setting a price target of $335. 
&#x2A; An analyst from TD Cowen persists with their Buy rating on Amgen, maintaining a target price of $383. 
&#x2A; Maintaining their stance, an analyst from UBS continues to hold a Neutral rating for Amgen, targeting a price of $326. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Amgen, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

AMGN

Amgen's Options Frenzy: What You Need to Know

Deep-pocketed investors have adopted a bullish approach towards Walmart (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in WMT usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 23 extraordinary options activities for Walmart. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 60% leaning bullish and 26% bearish. Among these notable options, 3 are puts, totaling $153,872, and 20 are calls, amounting to $2,986,061.
<h3>What's The Price Target?</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $60.0 to $86.67 for Walmart over the recent three months. 
<h3>Volume &amp; Open Interest Development</h3>
In today's trading context, the average open interest for options of Walmart stands at 10636.8, with a total volume reaching 97,378.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Walmart, situated within the strike price corridor from $60.0 to $86.67, throughout the last 30 days.
<h3>Walmart Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731600938_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>WMT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$2.57</td>
<td>$2.54</td>
<td>$2.57</td>
<td>$86.67</td>
<td>$476.0K</td>
<td>10.0K</td>
<td>3.6K</td>
</tr>
<tr>
<td>WMT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$2.59</td>
<td>$2.55</td>
<td>$2.58</td>
<td>$86.67</td>
<td>$464.9K</td>
<td>10.0K</td>
<td>6.6K</td>
</tr>
<tr>
<td>WMT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$2.57</td>
<td>$2.55</td>
<td>$2.58</td>
<td>$86.67</td>
<td>$398.6K</td>
<td>10.0K</td>
<td>1.6K</td>
</tr>
<tr>
<td>WMT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$2.58</td>
<td>$2.55</td>
<td>$2.58</td>
<td>$86.67</td>
<td>$231.9K</td>
<td>10.0K</td>
<td>4.6K</td>
</tr>
<tr>
<td>WMT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$2.59</td>
<td>$2.55</td>
<td>$2.58</td>
<td>$86.67</td>
<td>$206.6K</td>
<td>10.0K</td>
<td>7.5K</td>
</tr>
</tbody>
</table>

<h3>About Walmart</h3>
Walmart serves as the preeminent retailer in the United States, with its strategy predicated on superior operating efficiency and offering the lowest priced goods to consumers to drive robust store traffic and product turnover. Walmart augmented its low-price business strategy by offering a convenient one-stop shopping destination with the opening of its first supercenter in 1988.Today, Walmart operates over 4,600 stores in the United States (5,200 including Sam's Club) and over 10,000 stores globally. Walmart generated over $440 billion in domestic namesake sales in fiscal 2024, with Sam's Club contributing another $86 billion to the company's top line. Internationally, Walmart generated $115 billion in sales. The retailer serves around 240 million customers globally each week.
<h3>Walmart's Current Market Status</h3>
<ul>
<li>With a trading volume of 2,967,114, the price of WMT is up by 0.04%, reaching $85.53.</li>
<li>Current RSI values indicate that the stock is is currently neutral between overbought and oversold.</li>
<li>Next earnings report is scheduled for 5 days from now.</li>
</ul>
<h3>What Analysts Are Saying About Walmart</h3>
A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $89.2.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from Morgan Stanley continues to hold a Overweight rating for Walmart, targeting a price of $89. 
&#x2A; Consistent in their evaluation, an analyst from Keybanc keeps a Overweight rating on Walmart with a target price of $87. 
&#x2A; Maintaining their stance, an analyst from Telsey Advisory Group continues to hold a Outperform rating for Walmart, targeting a price of $92. 
&#x2A; An analyst from Wells Fargo has decided to maintain their Overweight rating on Walmart, which currently sits at a price target of $90. 
&#x2A; An analyst from Keybanc persists with their Overweight rating on Walmart, maintaining a target price of $88. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Walmart options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

What the Options Market Tells Us About Walmart

Nvidia&#8217;s CEO, Jensen Huang, shared something surprising during a Fireside Chat at the CASPA 2023 Annual <a href="https://www.youtube.com/watch?v=z8cAXOys3bI">Conference</a>. He said that Nvidia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) has no long-term plan. This might sound strange coming from the leader of a Big Tech company, but Huang had a simple reason: focus on the present.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Why Jensen Huang doesn't wear a watch: <a href="https://t.co/i1RW625mdI">pic.twitter.com/i1RW625mdI</a>
&mdash; Arjun Khemani (@arjunkhemani) <a href="https://twitter.com/arjunkhemani/status/1855613536187142367?ref_src=twsrc%5Etfw">November 10, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Don't Miss:
<ul>
<li>The global games market is projected to generate $272B by the end of the year —<a href="https://www.benzinga.com/money/gameflip"> for $0.55/share, this VC-backed startup with a 7M+ userbase gives investors easy access to this asset market.</a></li>
<li>With over 7.8K investors including Meta, Google, And Amazon Execs — this AI Startup's valuation has skyrocketed from $5 million to $85 million in just three years. <a href="https://www.benzinga.com/money/rad-ai">Be an early investor with just $1,000 for only $0.50/share today before the offer closes in 2 weeks.</a></li>
</ul>
Huang said that both in his personal life and in leading Nvidia, he doesn't believe in stressing over long-term plans. In fact, he doesn't even wear a watch – on purpose. This choice reflects his belief that the most important time is right now. This mindset, he says, is what <a href="https://www.benzinga.com/markets/equities/24/05/38911606/nvidias-2-trillion-success-story-how-an-act-of-kindness-from-a-top-sega-executive-saved-the-jens">has made Nvidia successful</a>, from graphics cards to artificial intelligence. Instead of worrying about the future, Nvidia works on solving today's problems in the best way possible.
This way of thinking has helped Nvidia become important in gaming, AI, robotics <a href="https://www.benzinga.com/markets/equities/24/09/40939729/energy-meets-ai-schlumberger-teams-up-with-nvidia-to-supercharge-industry-efficiency">and even climate modeling</a>. Huang explained that planning too far ahead can make you miss what's happening right before you. For Nvidia, it means staying flexible and being ready to jump on opportunities as they come – something that has worked well since they've adapted to meet the needs of fields like digital biology and AI.
Trending: Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target –<a href="https://www.benzinga.com/money/mode-mobile-2"> You can still get 4,000 of its pre-IPO shares for just $1,000</a>
&#8220;We don't have a long-term strategy,&#8221; Huang <a href="https://x.com/arjunkhemani/status/1855613536187142367">said</a>. &#8220;Our definition of a long-term plan is: what are we doing today?&#8221; By focusing on the present, Nvidia has led in areas like AI and accelerated computing that traditional computing hasn't kept up with.
Not having a strict plan doesn't mean Nvidia has no direction. Instead, it means they are always learning, changing and adjusting based on what's happening right before them. Huang said this approach is why <a href="https://www.benzinga.com/startups/24/09/40692021/nvidia-ceo-jensen-huang-will-push-employees-to-their-limits-but-is-reluctant-to-let-them-go-ill-tort">Nvidia keeps pushing limits</a>, especially with technologies like CUDA, which many doubted initially but <a href="https://www.benzinga.com/news/24/09/40692210/nvidia-maintains-ai-chip-dominance-as-huawei-struggles-to-compete-report">ended up changing computing</a>.
See Also: Warren Buffett once said, "If you don't find a way to make money while you sleep, you will work until you die." <a href="https://www.benzinga.com/money/connect-invest-real-estate-notes">These high-yield real estate notes that pay 7.5% &#8211; 9% make earning passive income easier than ever.</a>
Huang&#8217;s advice for young people or anyone who aspires to achieve was straightforward – concentrate on your current tasks. He thinks every day should be spent doing the finest work possible without worrying too much about the future. This doesn't mean you have no goals; instead, it means letting the present guide you. It's a refreshing way to look at life and work in a world where everyone seems to be rushing toward future goals without focusing on today.
Read Next:
<ul>
<li>‘Scrolling to UBI': Deloitte's #1 fastest-growing software company allows users to earn money on their phones –<a href="https://www.benzinga.com/money/mode-mobile-2"> invest today with $1,000 for just $0.25/share</a></li>
<li>This Adobe-backed AI marketing startup went from a $5 to $85 million valuation working with brands like L'Oréal, Hasbro, and Sweetgreen in just three years –<a href="https://www.benzinga.com/money/rad-ai"> here's how there's a limited time opportunity to invest at $1,000 for only $0.50/share before closing date.</a></li>
</ul>

Startups

NVDA

Jensen Huang Reveals 'Nvidia Doesn't Have A Long-Term Strategy' Or Plan. The Reason Behind It Is The Same For Why He Doesn't Wear A Watch

Canaccord Genuity analyst David Hynes maintains Zeta Global Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZETA#NYSE">ZETA</a>) with a Buy and lowers the price target from $42 to $24.

ZETA

Canaccord Genuity Maintains Buy on Zeta Global Holdings, Lowers Price Target to $24

Goldman Sachs analyst Mark Delaney maintains Innoviz Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INVZ#NASDAQ">INVZ</a>) with a Neutral and lowers the price target from $1 to $0.75.

INVZ

Goldman Sachs Maintains Neutral on Innoviz Technologies, Lowers Price Target to $0.75

Canaccord Genuity analyst Sumant Kulkarni maintains Voyager Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VYGR#NASDAQ">VYGR</a>) with a Buy and maintains $14 price target.

VYGR

Canaccord Genuity Maintains Buy on Voyager Therapeutics, Maintains $14 Price Target

Goldman Sachs analyst Eric Sheridan maintains Groupon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRPN#NASDAQ">GRPN</a>) with a Sell and lowers the price target from $11 to $8.

GRPN

Goldman Sachs Maintains Sell on Groupon, Lowers Price Target to $8

Analyst Ram Selvaraju of H.C. Wainwright reiterated a Buy rating on Reviva Pharmaceuticals Holdings (RVPH – Research Report), retaining the price t...

Buy Rating Reaffirmed for Reviva Pharmaceuticals: Patent Protection and Promising Drug Pipeline Fuel Positive Outlook

Analyst Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Reviva Pharmaceuticals Holdings (RVPH – Research Report) and keeping the pric...

Buy Rating Affirmed for Reviva Pharmaceuticals Amid Patent Grants and Positive Clinical Outlook

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Reviva Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/rvph-stock-quote/">RVPH</a>) just reported results for the second quarter of 2024.<ul><li>Reviva Pharmaceuticals reported earnings per share of -26 cents. This was above the analyst estimate for EPS of -29 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/rvph-stock-earnings-reviva-pharmaceuticals-for-q2-of-2024/">RVPH Stock Earnings: Reviva Pharmaceuticals Beats EPS for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

RVPH Stock Earnings: Reviva Pharmaceuticals Beats EPS for Q2 2024

Reviva Pharmaceuticals GAAP EPS of -$0.26

Reviva Pharmaceuticals stock falls after it prices $5M offering

The latest update is out from Reviva Pharmaceuticals Holdings (RVPH). Reviva Pharmaceuticals Holdings, Inc. has embarked on a financial maneuver wi...

Reviva Pharmaceuticals Launches Multi-Million Share Offering

In a report released yesterday, Jason McCarthy from Maxim Group maintained a Hold rating on Reviva Pharmaceuticals Holdings (RVPH – Research Report...

Maxim Group Reaffirms Their Hold Rating on Reviva Pharmaceuticals Holdings (RVPH)

Reviva Pharmaceuticals (RVPH) announced an enrollment update to the ongoing 1-year open-label extension, OLE, study evaluating the long-term safety...

Reviva announces enrollment update for OLE study of brilaroxazine

An announcement from Reviva Pharmaceuticals Holdings ( ($RVPH) ) is now available. Reviva Pharmaceuticals announced an enrollment update for its op...

Reviva Pharmaceuticals Progresses with Brilaroxazine Study Update

Maxim Group analyst Jason McCarthy maintained a Hold rating on Reviva Pharmaceuticals Holdings (RVPH – Research Report) yesterday. The company's sh...

Comments

Reviva Pharmaceuticals

Reviva Pharmaceuticals (RVPH) Opciones

Reviva Pharmaceuticals (NASDAQ:RVPH) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL